137 related articles for article (PubMed ID: 37698549)
21. PTEN/AKT signaling mediates chemoresistance in refractory acute myeloid leukemia through enhanced glycolysis.
Ryu MJ; Han J; Kim SJ; Lee MJ; Ju X; Lee YL; Son JH; Cui J; Jang Y; Chung W; Song IC; Kweon GR; Heo JY
Oncol Rep; 2019 Nov; 42(5):2149-2158. PubMed ID: 31545464
[TBL] [Abstract][Full Text] [Related]
22. Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death.
Heo SK; Noh EK; Yu HM; Kim DK; Seo HJ; Lee YJ; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
BMC Cancer; 2020 Dec; 20(1):1193. PubMed ID: 33276759
[TBL] [Abstract][Full Text] [Related]
23. miR-15a-5p and miR-21-5p contribute to chemoresistance in cytogenetically normal acute myeloid leukaemia by targeting PDCD4, ARL2 and BTG2.
Vandewalle V; Essaghir A; Bollaert E; Lenglez S; Graux C; Schoemans H; Saussoy P; Michaux L; Valk PJM; Demoulin JB; Havelange V
J Cell Mol Med; 2021 Jan; 25(1):575-585. PubMed ID: 33270982
[TBL] [Abstract][Full Text] [Related]
24. Critical role of Lama4 for hematopoiesis regeneration and acute myeloid leukemia progression.
Cai H; Kondo M; Sandhow L; Xiao P; Johansson AS; Sasaki T; Zawacka-Pankau J; Tryggvason K; Ungerstedt J; Walfridsson J; Ekblom M; Qian H
Blood; 2022 May; 139(20):3040-3057. PubMed ID: 34958665
[TBL] [Abstract][Full Text] [Related]
25. Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review.
Fajardo-Orduña GR; Ledesma-Martínez E; Aguiñiga-Sánchez I; Mora-García ML; Weiss-Steider B; Santiago-Osorio E
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34066940
[TBL] [Abstract][Full Text] [Related]
26. Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and transcriptional reprogramming and decreased mitochondrial function in acute myeloid leukemia.
Hege Hurrish K; Qiao X; Li X; Su Y; Carter J; Ma J; Kalpage HA; Hüttemann M; Edwards H; Wang G; Kim S; Dombkowski A; Bao X; Li J; Taub JW; Ge Y
Biochem Pharmacol; 2022 Nov; 205():115283. PubMed ID: 36208684
[TBL] [Abstract][Full Text] [Related]
27. Disruption of gap junctions attenuates acute myeloid leukemia chemoresistance induced by bone marrow mesenchymal stromal cells.
Kouzi F; Zibara K; Bourgeais J; Picou F; Gallay N; Brossaud J; Dakik H; Roux B; Hamard S; Le Nail LR; Hleihel R; Foucault A; Ravalet N; Rouleux-Bonnin F; Gouilleux F; Mazurier F; Bene MC; Akl H; Gyan E; Domenech J; El-Sabban M; Herault O
Oncogene; 2020 Feb; 39(6):1198-1212. PubMed ID: 31649334
[TBL] [Abstract][Full Text] [Related]
28. Hypermethylation of CpG sites at the promoter region is associated with deregulation of mitochondrial ATPsyn-β and chemoresistance in acute myeloid leukemia.
Yang J; Xiao X; Li R; Li Z; Deng M; Zhang G
Cancer Biomark; 2016; 16(1):81-8. PubMed ID: 26835708
[TBL] [Abstract][Full Text] [Related]
29. MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome.
Stavropoulou V; Kaspar S; Brault L; Sanders MA; Juge S; Morettini S; Tzankov A; Iacovino M; Lau IJ; Milne TA; Royo H; Kyba M; Valk PJM; Peters AHFM; Schwaller J
Cancer Cell; 2016 Jul; 30(1):43-58. PubMed ID: 27344946
[TBL] [Abstract][Full Text] [Related]
30. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
[TBL] [Abstract][Full Text] [Related]
31. The palmitoyltransferase ZDHHC21 regulates oxidative phosphorylation to induce differentiation block and stemness in AML.
Shao X; Xu A; Du W; Xu T; Huang Y; Xia Z; Wang W; Cai M; Zhang X; Zhang J; Cao J; Xu X; Yang B; He Q; Ying M
Blood; 2023 Jul; 142(4):365-381. PubMed ID: 37216691
[TBL] [Abstract][Full Text] [Related]
32. Targeting autophagy to overcome chemoresistance in acute myleogenous leukemia.
Piya S; Andreeff M; Borthakur G
Autophagy; 2017 Jan; 13(1):214-215. PubMed ID: 27797294
[TBL] [Abstract][Full Text] [Related]
33. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia.
Chen Y; Jacamo R; Konopleva M; Garzon R; Croce C; Andreeff M
J Clin Invest; 2013 Jun; 123(6):2395-407. PubMed ID: 23676502
[TBL] [Abstract][Full Text] [Related]
34. Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia.
Larrue C; Mouche S; Lin S; Simonetta F; Scheidegger NK; Poulain L; Birsen R; Sarry JE; Stegmaier K; Tamburini J
Leukemia; 2023 Apr; 37(4):765-775. PubMed ID: 36739349
[TBL] [Abstract][Full Text] [Related]
35. MiR-15a-5p Confers Chemoresistance in Acute Myeloid Leukemia by Inhibiting Autophagy Induced by Daunorubicin.
Bollaert E; Claus M; Vandewalle V; Lenglez S; Essaghir A; Demoulin JB; Havelange V
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068078
[TBL] [Abstract][Full Text] [Related]
36. Tumor-suppressive MEG3 induces microRNA-493-5p expression to reduce arabinocytosine chemoresistance of acute myeloid leukemia cells by downregulating the METTL3/MYC axis.
Wang A; Chen Y; Shi L; Li M; Li L; Wang S; Wang C
J Transl Med; 2022 Jun; 20(1):288. PubMed ID: 35761379
[TBL] [Abstract][Full Text] [Related]
37. HOTAIRM1 knockdown enhances cytarabine-induced cytotoxicity by suppression of glycolysis through the Wnt/β-catenin/PFKP pathway in acute myeloid leukemia cells.
Chen L; Hu N; Wang C; Zhao H
Arch Biochem Biophys; 2020 Feb; 680():108244. PubMed ID: 31904363
[TBL] [Abstract][Full Text] [Related]
38. Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML).
Zhu KW; Chen P; Zhang DY; Yan H; Liu H; Cen LN; Liu YL; Cao S; Zhou G; Zeng H; Chen SP; Zhao XL; Chen XP
J Transl Med; 2018 Apr; 16(1):90. PubMed ID: 29631596
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells.
Li P; Diab S; Yu M; Adams J; Islam S; Basnet SK; Albrecht H; Milne R; Wang S
Oncotarget; 2016 Aug; 7(35):56811-56825. PubMed ID: 27462781
[TBL] [Abstract][Full Text] [Related]
40. [Identification of GPAT1-dependent mitochondrial metabolism as a novel therapeutic target for AML].
Irifune H
Rinsho Ketsueki; 2022; 63(5):353-362. PubMed ID: 35662157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
